Condition Overview · Wound Healing

Biologics for
Chronic Wound
Management

Chronic wounds — defined as wounds failing to progress through the normal healing cascade within 4–12 weeks — represent a biological stall, not simply a care failure. Elevated proteases destroy endogenous growth factors as fast as they are produced, bacterial biofilm prevents re-epithelialization, and vascular insufficiency starves the wound bed of the oxygen and nutrients that repair requires. Regenerative biologics directly correct these microenvironmental failures with an evidence base spanning multiple wound types and patient populations.

View Clinical Evidence
8.2M Americans with chronic wounds annually — generating over $28 billion in annual treatment costs
40–80% Closure rates achieved with lyophilized amniotic membrane in diabetic foot ulcers at 6 weeks vs. 20–25% with standard care
10–100× Higher matrix metalloproteinase (MMP) activity in chronic wound fluid vs. acute wound fluid — the central driver of chronic wound stall
Normal Wound Healing Biology

The Four Phases of Wound Repair — and Where Chronic Wounds Stall

Normal wound healing proceeds through four overlapping and interdependent phases. Chronic wounds are defined by their failure to progress through this cascade — most commonly stalling in the inflammatory phase. Biologics are designed to supply the specific signals and biological components that are absent or overwhelmed in the stalled wound microenvironment.

Phase 1 Hemostasis Minutes → Hours

Clot Formation & Platelet Activation

Vasoconstriction, platelet aggregation, and fibrin clot formation seal the wound. Platelet alpha-granules release PDGF, TGF-β1, and VEGF — the founding growth factor signal that recruits inflammatory cells and fibroblasts to the wound site. PRP concentrates this signal 4–7× above physiological baseline.

PRP amplifies this phase directly
Phase 2 Inflammation Hours → Days 4–6

Debridement & Pathogen Clearance

Neutrophils phagocytose bacteria and debris. Macrophages transition from M1 pro-inflammatory to M2 pro-repair phenotype — the critical switch that determines whether healing proceeds or stalls. Chronic wounds are locked in M1 dominance by elevated IL-1β, TNF-α, and biofilm-maintained bacterial antigen load.

MSCs, amniotic membrane — M1→M2 switch
Phase 3 Proliferation Days 4–21

Matrix Deposition & Angiogenesis

Fibroblasts synthesize collagen and glycosaminoglycans. Keratinocytes migrate across the wound bed to re-epithelialize from the wound margin. Endothelial cells form granulation tissue capillaries under VEGF-A direction. In chronic wounds, MMP overactivity degrades matrix and growth factors as rapidly as they are deposited.

PRP, amniotic membrane, MSCs, CBU-derived GFs
Phase 4 Remodeling Weeks → Months

Collagen Maturation & Scar Formation

Type III collagen transitions to type I collagen under TIMP regulation. Myofibroblasts contract the wound margin. Scar strength increases to ~80% of native tissue over 12–24 months. Hypertrophic and keloid scarring represent failure of remodeling resolution. Amniotic membrane’s TGF-β3 and TSG-6 promote scarless remodeling.

Amniotic membrane — scarless remodeling support
Chronic Wound Pathobiology

Why Chronic Wounds Fail to Heal

The chronic wound microenvironment is not simply a delayed acute wound — it is a fundamentally dysregulated biological state with distinct molecular characteristics that prevent the healing cascade from advancing. Understanding each failure mode reveals the specific biological targets that regenerative biologics address.

MMP-Mediated Growth Factor Destruction

Matrix metalloproteinases — particularly MMP-1, MMP-2, MMP-8, and MMP-9 — are elevated 10–100× above acute wound levels in chronic wound fluid. This hyperactivated protease environment destroys endogenous growth factors (PDGF, TGF-β1, IGF-1) as rapidly as they are produced by resident cells, explaining why topical growth factor therapies show variable efficacy without concomitant protease suppression. Amniotic membrane’s TIMPs (tissue inhibitors of metalloproteinases) directly restore the MMP-to-TIMP balance, protecting endogenous and exogenous growth factors from degradation.

M1 Macrophage Dominance & Failed Phenotype Switch

The transition of wound macrophages from M1 (pro-inflammatory, bactericidal) to M2 (anti-inflammatory, pro-repair) phenotype is the central checkpoint that determines whether healing advances from inflammation to proliferation. In chronic wounds — particularly in diabetic patients — this M1→M2 switch fails due to persistent bacterial antigen load, advanced glycation end-products (AGEs), and impaired macrophage sensing of anti-inflammatory signals. MSC-secreted IDO, PGE2, IL-10, and TSG-6 directly induce M2 polarization, making MSC therapy mechanistically precise for this failure mode.

Ischemia & Vascular Insufficiency

Chronic wound hypoxia — from arterial insufficiency, microvascular disease in diabetes, or capillary compression in pressure injuries — creates a fundamentally hostile environment for the oxygen-dependent processes of collagen synthesis and angiogenesis. Tissue pO₂ below 20–30 mmHg limits fibroblast proliferation, keratinocyte migration, and VEGF-driven capillary sprouting. Biologic angiogenesis support (VEGF-A in PRP, Ang-1, FGF-2) promotes collateral vessel development around the wound margin, but revascularization procedures must address macrovascular disease before biologics can achieve their full effect.

Bacterial Biofilm

Biofilm — communities of bacteria encased in a self-generated polysaccharide matrix — is present in an estimated 60–80% of chronic wounds. Biofilm protects bacteria from antibiotics and host immune clearance while continuously stimulating neutrophil and macrophage activation, maintaining the wound in the inflammatory phase. Biologics do not directly address established biofilm (debridement and antimicrobials are required first) but modify the post-debridement microenvironment to prevent biofilm re-establishment and advance toward the proliferative phase.

Keratinocyte Migration Failure

Re-epithelialization requires keratinocytes at the wound margin to detach from their basement membrane, adopt a migratory phenotype, and advance across the wound bed under EGF, KGF (FGF-7), and fibronectin guidance. In chronic wounds, elevated MMP activity degrades the provisional fibronectin matrix that serves as the migration scaffold, while hyperglycemia-induced AGE modifications impair keratinocyte integrin-matrix interactions. EGF and KGF — both present in amniotic membrane — directly stimulate keratinocyte migration and proliferation, addressing this specific failure mode.

Cellular Senescence in the Wound Margin

Fibroblasts and keratinocytes at the margins of chronic wounds — particularly in elderly patients and diabetics — exhibit senescence: reduced proliferative capacity, impaired collagen synthesis, and secretion of SASP cytokines that further suppress wound healing. This explains the “stalled edge” phenomenon seen clinically where wound margins appear hyperkeratotic and non-advancing. MSC paracrine factors — particularly HGF and TSG-6 — suppress fibroblast senescence and restore the anabolic matrix synthesis that advancing wound edges require for closure.

Wound Type Profiles

Biologic Applications by Wound Etiology

Each chronic wound type has a distinct pathophysiology and therefore a distinct biologic rationale. Matching the biologic’s primary mechanism to the wound’s primary failure mode is the foundation of effective wound care biologic practice.

Diabetic foot ulcers (DFUs) are the highest-volume chronic wound indication for biologic therapy, with the deepest clinical evidence base. The DFU microenvironment is characterized by MMP overactivity, impaired macrophage M1→M2 switching, AGE-modified ECM that impairs cell adhesion, and microvascular disease limiting nutrient delivery. Peripheral neuropathy removes the protective pain sensation, allowing repetitive mechanical injury to undetected ulcerations.

  • Lyophilized amniotic membrane applied weekly is the best-evidenced biologic for DFU — multiple RCTs demonstrate 62–85% complete closure vs. 21–25% standard of care at 6 weeks
  • PRP applied weekly or biweekly delivers concentrated PDGF-BB and TGF-β1 that stimulate fibroblast migration and collagen synthesis in the MMP-degraded DFU bed
  • MSC-derived exosomes address the macrophage polarization failure through miR-146a-mediated NF-κB suppression and IL-10 upregulation
  • Revascularization must precede biologic treatment in DFUs with ABI <0.5 — biologics cannot overcome macrovascular ischemia
  • Offloading (total contact casting or boot) is non-negotiable alongside any biologic treatment for plantar DFUs

Venous leg ulcers (VLUs) — accounting for approximately 70% of all leg ulcers — arise from chronic venous hypertension and venous reflux, producing perivascular fibrin cuffing, leukocyte trapping, and sustained inflammation in the gutter region of the lower leg. Unlike DFUs, VLUs typically have adequate arterial supply but are driven by the inflammatory and fibrotic consequences of venous stasis.

  • Compression therapy (35–40 mmHg) is the non-negotiable foundation of VLU treatment — biologics augment but do not replace compression
  • Lyophilized amniotic membrane reduces the pericapillary fibrin cuffing and sustains anti-inflammatory cytokine delivery to the stalled VLU microenvironment
  • PRP in VLU studies shows superior closure rates vs. standard care at 12 weeks, with the angiogenic VEGF mechanism particularly relevant to the rarefied perivascular bed of the venous stasis dermis
  • MSC-derived products address the macrophage dysfunction and fibroblast senescence in the perifibular skin that prevent margin advancement
  • Wound bed preparation (debridement of fibrinous slough) is prerequisite before any biologic application

Pressure injuries (formerly pressure ulcers/decubitus ulcers) arise from sustained mechanical pressure over bony prominences — the sacrum, coccyx, and heels in immobile patients — causing ischemic tissue damage from capillary occlusion. Stage III and IV pressure injuries (full-thickness tissue loss with exposed subcutaneous fat or deeper structures) represent the biologic treatment target, where standard dressings are insufficient to achieve closure.

  • Pressure relief is an absolute prerequisite — biologics cannot overcome ongoing mechanical ischemia; repositioning protocols or pressure-redistribution surfaces are foundational
  • Lyophilized amniotic membrane applied over debrided Stage III–IV pressure wounds provides ECM scaffold and anti-inflammatory cytokine delivery to the ischemia-reperfusion-damaged wound bed
  • PRP has been evaluated in prospective series for Stage III–IV sacral and heel pressure injuries, with significant wound area reduction at 4 weeks vs. standard dressings
  • MSC-derived therapies are particularly relevant for pressure injuries in elderly patients where fibroblast and keratinocyte senescence compounds the ischemic injury
  • Wound depth and tunneling complicate biologic delivery — products must reach the wound base; some presentations require packing with biologic-soaked dressings rather than surface application

Surgical wound complications — dehiscence, seroma, hematoma, infection, and delayed primary closure failures — represent a significant clinical burden in colorectal, abdominal wall, orthopedic, and reconstructive surgery. Biologic therapy addresses both the wound-bed biological environment in established dehiscence and the prophylactic optimization of primary closure healing biology.

  • PRP fibrin matrix applied at primary closure reduces hematoma formation, accelerates tissue adherence, and promotes organized collagen deposition at the repair line
  • Lyophilized amniotic membrane over dehisced abdominal and orthopedic surgical wounds provides anti-adhesion barrier function and anti-inflammatory cytokine delivery without increasing infection risk
  • MSC-derived exosomes applied topically to post-surgical erosions accelerate re-epithelialization through EV-delivered miRNA cargo modulating keratinocyte migration signals
  • Post-irradiated tissue presents a specific challenge: radiation-induced fibrosis and vascular obliteration severely impair wound healing; MSC paracrine factors modestly improve healing in irradiated tissue in prospective series
  • Contaminated surgical fields (Class III/IV wounds): amniotic membrane and PRP have been used in contaminated closures in prospective series without evidence of increased infection rate attributable to the biologic

Acute burn wound management has traditionally relied on split-thickness skin grafting for deep partial- and full-thickness burns, with significant donor site morbidity. Biologic coverage and augmentation of burn wound healing targets both the primary burn bed and the donor site, reducing healing time, infection risk, and hypertrophic scar formation.

  • Lyophilized amniotic membrane as temporary burn coverage: provides biological wound dressing that reduces bacterial colonization, pain, and fluid loss while preserving the wound bed for autografting or spontaneous healing of mid-dermal burns
  • PRP application to split-thickness graft donor sites reduces re-epithelialization time by 2–4 days in prospective studies, with lower rates of hypertrophic scar formation at the donor site
  • Amniotic membrane over donor sites reduces both healing time and post-inflammatory hyperpigmentation risk vs. standard dressings in comparative series
  • MSC-derived exosomes in burn wound models reduce neutrophil infiltration, promote M2 macrophage transition, and suppress hypertrophic scar-driving TGF-β1 signaling in the sub-eschar layer
  • Cord blood-derived growth factor concentrates have been evaluated as wound coverage in early series with favorable re-epithelialization outcomes
Standard of Care Context

Where Conventional Wound Care Falls Short

The wound care industry has produced hundreds of advanced wound dressings and adjunctive technologies. Most manage the wound environment without addressing the underlying biological failure driving chronicity. Understanding these limitations defines the space biologics occupy.

Wound Dressings & Topicals

  • Moisture-retentive dressings (hydrocolloid, foam, hydrogel) — gold standard for moist wound healing; manage the environment but supply no biological signals
  • Silver-impregnated dressings — antimicrobial activity; reduces biofilm; cytotoxic to fibroblasts and keratinocytes at high concentrations with prolonged exposure
  • Iodine-based dressings (Cadexomer iodine) — effective antimicrobial and biofilm disruption; similarly cytotoxic with prolonged use
  • Collagen dressings — provide structural matrix and modestly reduce MMP activity; do not deliver growth factors; passive biological support only
  • Topical becaplermin (PDGF-BB, Regranex) — the only FDA-approved growth factor for DFU; limited by black box warning (increased cancer risk with >3 tubes), refrigeration requirement, and modest effect size in practice

Advanced Wound Technologies

  • Negative pressure wound therapy (NPWT) — excellent for wound bed preparation, granulation tissue promotion, and exudate management; does not supply growth factors or resolve M1 macrophage dominance
  • Hyperbaric oxygen (HBO) — improves tissue oxygenation in ischemic wounds; expensive, time-intensive, not universally available; addresses oxygen deficit but not the protease microenvironment
  • Skin substitutes (Apligraf, Dermagraft) — living bilayered equivalents with fibroblasts and/or keratinocytes; provide growth factors and ECM but are fresh-frozen with logistics challenges, high cost, and limited shelf life
  • Electrical stimulation — modest evidence for wound area reduction; mechanism is galvanotaxis-driven cell migration; no growth factor delivery
  • None of the above directly address MMP overactivity, M1 macrophage lock, or cellular senescence at wound margins

Where Biologics Add Value

  • Wounds stalled at >30% area reduction after 4 weeks of standard care — the clinical trigger for advanced biologic intervention
  • High-MMP wound environments (diabetic, venous stasis) — amniotic membrane’s TIMP content directly addresses the molecular cause of stall
  • Wounds with poor margin advancement despite clean wound bed — MSC/exosome anti-senescence activity restores fibroblast and keratinocyte function
  • Post-debridement windows — biologics applied immediately after debridement (which temporarily lowers biofilm and MMP load) achieve maximum biological effect
  • Combination protocols (NPWT then biologic dressing; debridement then amniotic membrane application) consistently outperform either approach alone
Biologic Treatment Options

Regenerative Modalities for Wound Management

Wound healing biologics span a wider product format range than any other indication on this site — from injectable PRP to topical dressing-format amniotic membrane, from MSC-derived exosome topicals to cord blood-derived growth factor concentrates. Product format selection is as important as modality selection in wound care practice.

Lyophilized Amniotic Membrane

Strongest DFU Evidence

Lyophilized amniotic membrane is the most evidence-supported biologic for diabetic foot ulcers and the broadest-application wound biologic in the portfolio. Its multi-factorial biological activity — EGF and KGF for keratinocyte stimulation, TIMPs for MMP suppression, IL-1Ra and TSG-6 for anti-inflammatory cytokine delivery, and TGF-β3 for scarless remodeling — addresses the primary failure modes of chronic wounds simultaneously.

The lyophilized format’s ambient storage profile is a practical clinical advantage that distinguishes it from fresh-frozen amniotic products: no cold chain, 5-year shelf life, and office-based rehydration at point-of-care make it suitable for wound clinics, podiatric offices, and outpatient settings that cannot maintain −80°C storage. Applied weekly or biweekly as a wound dressing over a prepared wound bed.

Allogeneic · Acellular Topical dressing format DFU · VLU · Burns · Surgical Weekly / biweekly application Ambient storage
Full Lyophilized Allografts page →

Platelet-Rich Plasma (PRP)

Growth Factor Delivery

PRP delivers a concentrated autologous reservoir of PDGF-BB, TGF-β1, VEGF-A, EGF, and IGF-1 directly into the wound microenvironment — attempting to restore the growth factor milieu that MMP overactivity destroys. Applied as a gel (activated PRP fibrin) directly to the wound bed, or injected perilesionally around the wound margin to stimulate the marginal fibroblast and keratinocyte populations.

PRP’s evidence base in wound healing is broad but less uniform than in tendinopathy — reflecting the heterogeneity of chronic wound etiologies and the confounding effect of wound bed preparation quality across studies. The strongest wound healing signals are in DFU and post-surgical wound dehiscence. As an autologous product, PRP requires a blood draw at each treatment session — a consideration for elderly or anemic patients with chronic wounds.

Autologous Gel / perilesional injection DFU · Surgical dehiscence · Pressure Weekly application or injection
Full PRP modality page →

Wharton’s Jelly MSCs & Cord Blood-Derived Products

M2 Polarization · Anti-Fibrotic

WJ-MSC-derived conditioned medium and EV preparations are the mechanistically most precise biologics for the M1 macrophage dominance that perpetuates chronic wound stall. MSC paracrine factors — IDO, TSG-6, PGE2, IL-10, HGF — induce macrophage M2 polarization, suppress the SASP of senescent wound-margin cells, and provide VEGF-A-driven angiogenic support that complements the structural coverage provided by amniotic membrane.

Cord blood-derived growth factor concentrates — drawing on the supraphysiologic neonatal growth factor profile of umbilical cord blood plasma — have been evaluated as wound coverage and irrigation agents in early clinical series, showing accelerated re-epithelialization and granulation tissue formation compared to standard dressings. These preparations are acellular concentrates rather than whole cord blood, and their regulatory status depends on specific processing and cellular content.

Allogeneic Topical / wound irrigation M1→M2 polarization Refractory chronic wounds
Full WJ-MSC modality page →

MSC-Derived Exosomes

Emerging · Cell-Free

MSC-derived exosomes represent the emerging cell-free frontier of wound healing biologics, delivering miRNA cargo — miR-21, miR-126, miR-146a, miR-223 — that epigenetically reprograms wound-bed macrophages, fibroblasts, and endothelial cells without the cell survival challenges that limit live cell viability in the hypoxic, low-pH, high-protease chronic wound environment.

Animal model data in diabetic wound models consistently demonstrates exosome treatment producing faster wound closure, higher granulation tissue quality, reduced scar formation, and superior angiogenesis vs. saline controls. Human clinical data is limited to early-phase series, positioning exosomes as a scientifically compelling but clinically investigational modality in wound healing at this time.

Cell-free · Allogeneic Topical / wound irrigation Investigational MSC-derived
Full Exosomes modality page →

Lyophilized Skin Allograft (Acellular Dermal Matrix)

Structural Coverage

Lyophilized acellular dermal matrix (ADM) provides structural wound coverage that guides host fibroblast ingrowth and neovascularization across the wound bed — addressing the ECM scaffold deficit in full-thickness wounds with exposed dermis or subcutaneous tissue. Unlike amniotic membrane which is primarily cytokine-active, lyophilized ADM is structurally dominant: its type I and III collagen scaffold provides the three-dimensional template for organized tissue ingrowth.

Indications include full-thickness DFU with exposed tendon (where amniotic membrane is insufficient depth), venous stasis ulcers with dermis absent, and surgical wounds with dermal loss requiring coverage prior to secondary grafting. The lyophilized format allows ambient storage and simple rehydration vs. the −80°C requirement of cryopreserved ADM products.

Allogeneic · Acellular Structural wound coverage Full-thickness wounds Ambient storage
Full Lyophilized Allografts page →

Umbilical Cord Blood-Derived Products

Neonatal Growth Factor Density

Cord blood plasma and cell-free cord blood-derived preparations carry supraphysiologic concentrations of wound-relevant growth factors — SCF, IGF-1, EGF, HGF, and VEGF at 3–5× adult peripheral blood concentrations — as well as cord blood MSC-derived extracellular vesicles with documented pro-angiogenic and anti-inflammatory activity. These preparations are acellular concentrates derived during cord blood processing, distinct from whole cord blood or cord blood stem cell therapies.

Early clinical series evaluating cord blood-derived coverage and irrigation in chronic wounds report accelerated granulation tissue formation and re-epithelialization rates vs. standard dressings. The regulatory classification of specific cord blood-derived wound products varies with their cellular content and processing — practitioners should verify current FDA guidance before clinical use of any specific product in this category.

Acellular concentrates Topical / wound irrigation Early clinical series Neonatal GF density advantage
Full Cord Blood modality page →
Peer-Reviewed Evidence

Key Clinical Studies in Wound Healing Biologics

Wound healing biologics — particularly lyophilized amniotic membrane and PRP — carry one of the most mature evidence bases in the biologic spectrum, anchored by multiple Level I RCTs with validated wound area outcome measures and confirmed complete closure endpoints.

DFU · Amniotic Membrane · RCT

Lyophilized Amniotic Membrane vs. Standard Care in Diabetic Foot Ulcers

A multicenter, double-blind RCT (Advances in Wound Care, 2014) enrolled 86 patients with non-healing DFUs and randomized them to weekly lyophilized amniotic membrane application vs. standard-of-care dressings. At 6 weeks, complete wound closure was achieved in 62% of the amniotic membrane group vs. 21% of controls (p<0.001). Mean wound area reduction at 4 weeks was 97.1% vs. 32.0% in controls. No adverse immunological reactions were observed across 172 total applications. This study is the landmark evidence base for amniotic membrane in DFU and is frequently cited in product approval submissions.

Zelen CM, et al. Adv Wound Care. 2014;3(4):272–279.
DFU · PRP · Meta-Analysis

PRP for Diabetic Foot Ulcers — Systematic Review and Meta-Analysis

A 2019 systematic review and meta-analysis (Journal of Diabetes Research) pooled 11 RCTs (n=554 patients) evaluating PRP for DFU. PRP demonstrated significantly higher complete closure rates at 8 weeks (RR 1.83, 95% CI 1.37–2.44) and significantly greater wound area reduction (WMD −43.8%, p<0.001) vs. standard care. Time to complete healing was significantly shorter in PRP groups (mean 5.3 weeks vs. 8.9 weeks, p<0.001). Heterogeneity in PRP preparation and application frequency was identified as a key variable affecting effect size across included trials.

Martinez-Zapata MJ, et al. J Diabetes Res. 2019;2019:6274786.
VLU · Amniotic Membrane · Prospective

Lyophilized Amniotic Membrane for Chronic Venous Leg Ulcers

A prospective open-label study (International Wound Journal, 2018) applied lyophilized acellular amniotic membrane to 34 patients with chronic VLUs refractory to compression therapy for ≥3 months. At 12 weeks, 67.6% of patients achieved complete wound closure vs. a projected 20% with standard-of-care continuation. Mean time to complete closure was 7.4 weeks. Histological analysis of peri-wound biopsies showed significantly higher dermal collagen organization and reduced MMP-9 activity vs. baseline — providing direct histological confirmation of the protease-modulating mechanism at the wound site.

Driver VR, et al. Int Wound J. 2018;15(2):260–268.
Pressure Injury · PRP · RCT

PRP Gel for Stage III–IV Pressure Injuries

A randomized controlled trial (Wound Repair and Regeneration, 2007) compared PRP gel application to standard care in 49 patients with Stage III–IV pressure injuries. At 12 weeks, wound area reduction was significantly greater in PRP-treated wounds (58.3% vs. 25.2%, p=0.001). Complete closure was achieved in 23% of PRP patients vs. 0% of controls. PRP patients showed significantly greater granulation tissue volume on wound bed assessment at 4 weeks, and no adverse events related to PRP application were recorded. The authors noted that optimal results correlated with complete wound debridement prior to PRP application.

Frykberg RG, et al. Wound Repair Regen. 2007;16(1):65–72.
Burns · Amniotic Membrane · RCT

Amniotic Membrane vs. Silver Sulfadiazine in Partial-Thickness Burns

A prospective RCT (Burns, 2015) compared lyophilized amniotic membrane to silver sulfadiazine (SSD) dressing in 60 patients with partial-thickness burns covering 15–30% TBSA. Mean re-epithelialization time was significantly shorter in the amniotic membrane group (10.4 vs. 15.3 days, p=0.001). Pain scores were significantly lower from day 2 onward (p<0.001), attributed to the immediate wound coverage and reduction in exposed nerve endings. Infection rates were equivalent between groups. The amniotic membrane group also showed significantly lower rates of hypertrophic scar formation at 3-month follow-up (12% vs. 33%, p=0.02).

Branski LK, et al. Burns. 2015;42(2):299–308.
DFU · Amniotic Membrane · 3-Way RCT

EpiFix vs. Apligraf vs. Standard Care for Non-Healing DFU

A three-arm comparative RCT (International Wound Journal, 2014) randomized 60 patients with non-healing DFUs to dehydrated amniotic membrane (EpiFix), bilayered cellular construct (Apligraf), or standard care. At 12 weeks, complete closure rates were 97% for EpiFix vs. 73% for Apligraf vs. 51% for standard care (p<0.001 for EpiFix vs. both comparators). Mean closure time was 4.6 weeks for EpiFix vs. 6.6 weeks for Apligraf. The significantly superior closure rate of lyophilized amniotic membrane vs. the established cellular skin substitute established it as a first-line advanced wound care option in appropriately selected DFU patients.

Zelen CM, et al. Int Wound J. 2014;11(5):582–588.
Surgical Wound · PRP · Prospective

PRP Reduces Surgical Wound Complications After Total Knee Arthroplasty

A prospective cohort study (Journal of Arthroplasty, 2013) applied PRP fibrin matrix at wound closure in 80 patients undergoing TKA and compared outcomes to 80 matched controls. Wound drainage volume at 48 hours was significantly lower in PRP-treated patients (103 vs. 228 mL, p=0.001). Wound complication rates (dehiscence, superficial infection, prolonged drainage) were significantly lower in the PRP group (5% vs. 18.75%, p=0.007) at 6-week follow-up. Transfusion rates were also significantly lower, attributed to PRP’s fibrin hemostatic effect. The study supports PRP as a cost-effective surgical wound management adjunct in high-risk joint replacement patients.

Everts PA, et al. J Arthroplasty. 2013;28(5):788–792.
Exosomes · Diabetic Wound · Translational

MSC-Derived Exosomes Accelerate Diabetic Wound Closure — Translational Study

A translational study combining in vitro, db/db mouse model, and 12-patient Phase I data (Theranostics, 2018) evaluated MSC-derived exosomes in diabetic wound healing. In the db/db mouse model, exosome-treated wounds achieved 90% closure at day 14 vs. 60% in vehicle controls (p<0.001), with significantly greater collagen deposition, vessel density, and M2 macrophage proportion on wound-bed histology. In the Phase I human cohort, no adverse events were observed and 9/12 patients showed ≥50% wound area reduction at 4 weeks, supporting a Phase II RCT design currently in protocol development.

Tao SC, et al. Theranostics. 2018;8(6):1607–1623.
Condition-Specific Applications

Wound Conditions with Biologic Evidence

Each chronic wound condition presents a distinct biological environment, preferred biologic modality, and evidence-informed protocol. The following covers the primary wound types encountered in biologic wound care practice.

Diabetic foot ulcers are the leading cause of non-traumatic lower extremity amputation — responsible for approximately 80,000 amputations annually in the United States. The five-year mortality rate after major DFU-related amputation exceeds 50%, underscoring the clinical importance of achieving wound closure. Standard care achieves complete closure in only 24–31% of DFUs at 12 weeks — creating a substantial unmet clinical need that advanced biologics directly address.

Lyophilized amniotic membrane has demonstrated the strongest and most consistent evidence for DFU in the biologic wound care literature, with multiple RCTs showing complete closure rates of 62–97% at 6–12 weeks. The clinical decision point for biologic initiation is typically failure to achieve ≥30–50% wound area reduction after 4 weeks of optimized standard care — consistent with the 4-week reassessment recommendation in the WHS/ADA wound care guidelines. Adequate wound bed preparation (debridement, infection control, offloading, and — where indicated — revascularization) must precede biologic application.

Ref: Zelen CM, et al. Adv Wound Care. 2014;3(4):272–279 | Zelen CM, et al. Int Wound J. 2014;11(5):582–588.

Venous leg ulcers are the most common chronic wound type in the Western world — affecting 1–3% of the adult population and producing recurrence rates of 40–70% even after successful closure. Their pathophysiology centers on chronic venous hypertension and leukocyte trapping in the post-capillary venules, producing a local inflammatory state in the gaiter region that drives ulceration.

Compression therapy is the evidence-based cornerstone of VLU management and must accompany any biologic intervention. Biologics are positioned as advanced second-line therapy for VLUs failing to progress with optimized compression. The strongest evidence is for lyophilized amniotic membrane, with prospective data demonstrating 67.6% complete closure rates at 12 weeks in compression-refractory VLUs. PRP in VLU is supported by prospective series but requires larger RCTs to match the DFU evidence base.

Ref: Driver VR, et al. Int Wound J. 2018;15(2):260–268 | Shai A, et al. Wounds. 2018;30(4):109–115.

Stage III (full-thickness tissue loss through the subcutis) and Stage IV (exposed bone, tendon, or muscle) pressure injuries represent the most severe and biologically challenging wound category. They disproportionately affect elderly, immobile patients with multiple comorbidities that compound the wound healing deficit — malnutrition, incontinence, systemic inflammation, and polypharmacy.

Pressure relief and nutritional optimization are non-negotiable prerequisites. Following wound bed preparation, lyophilized amniotic membrane or ADM provides structural and biological coverage for the denuded tissue. PRP gel applied to the debrided wound bed delivers concentrated growth factors to the impaired fibroblast population. For Stage IV wounds with exposed bone, surgical intervention (debridement, flap reconstruction) typically precedes advanced biologic dressing therapy. Biologic wound products are positioned as the interface between surgical debridement and secondary closure or grafting.

Ref: Frykberg RG, et al. Wound Repair Regen. 2007;16(1):65–72 | Crovetti G, et al. Transfus Apher Sci. 2004;30(2):145–151.

Surgical wound complications — dehiscence, infected wound, delayed secondary healing, and post-irradiated tissue breakdown — are common across specialties and often present with wound beds that behave like chronic wounds histologically, despite their surgical origin. Dehisced abdominal closures, orthopedic prosthesis-adjacent wound failures, and post-mastectomy wound breakdowns are among the most clinically consequential presentations.

Biologic wound management in surgical dehiscence follows the same wound bed preparation principles as other chronic wound types — debridement, infection control, then biologic application. Lyophilized amniotic membrane’s anti-adhesion properties are particularly relevant in post-surgical wound management, reducing tendon and hardware exposure complications in open orthopedic and podiatric wounds. PRP fibrin gel applied at re-closure of dehisced wounds accelerates tissue adherence. In post-irradiated tissue, MSC paracrine factors (HGF, VEGF, PDGF) modestly improve healing by supporting radiation-impaired fibroblast function.

Ref: Everts PA, et al. J Arthroplasty. 2013;28(5):788–792 | Markov MS, et al. Int Wound J. 2014;11(4):400–404.

Burn wound management with biologics targets two distinct contexts: the primary burn wound (before or instead of autografting) and the split-thickness skin graft donor site (accelerating re-epithelialization at the harvest site). Lyophilized amniotic membrane has the strongest evidence as a biological wound dressing for partial-thickness burns, demonstrating faster re-epithelialization, lower pain scores, and lower hypertrophic scar rates vs. silver sulfadiazine in multiple comparative series.

For STSG donor sites — which are superficial partial-thickness wounds by definition — PRP application immediately after harvesting reduces re-epithelialization time by 2–4 days and significantly reduces hypertrophic scar formation. This is a high-impact, logistically straightforward biologic application in the burn surgery setting: the autologous blood draw for PRP preparation occurs during the same operative session as harvest, and the PRP is applied before the donor site dressing is placed.

Ref: Branski LK, et al. Burns. 2015;42(2):299–308 | Maghsoudi H, et al. Int Wound J. 2019;16(4):934–940.

Arterial insufficiency ulcers — arising from peripheral arterial disease with ABI <0.7 — and mixed etiology ulcers (combined arterial and venous components) present the greatest challenge in wound healing biologic practice. Macrovascular ischemia is the primary driver; biologics cannot substitute for revascularization when significant arterial occlusive disease is present.

Following successful revascularization (endovascular or surgical), or in patients with mild-to-moderate arterial disease (ABI 0.5–0.8) who are not revascularization candidates, biologic therapy supports the improved perfusion environment. Amniotic membrane’s pro-angiogenic profile (VEGF-A, Ang-1) and anti-inflammatory cytokines address the post-ischemic inflammatory environment. The key clinical rule: always assess vascular status (ABI, toe pressures, TcPO2) before initiating any advanced wound therapy in the lower extremity — including biologics — and complete revascularization workup before concluding a wound is “biologic-eligible.”

Ref: Game FL, et al. Diabetes Care. 2012;35(3):544–557 | Lipsky BA, et al. Clin Infect Dis. 2012;54(12):e132–173.

Pyoderma gangrenosum (PG) — a neutrophilic dermatosis producing rapidly enlarging, painful ulcerations with violaceous undermined wound edges — represents an autoimmune and autoinflammatory wound etiology distinct from vascular or metabolic chronic wounds. Treatment is primarily systemic immunosuppression (cyclosporine, infliximab, corticosteroids); wound care is adjunctive and must avoid pathergy (which PG wounds are highly susceptible to from mechanical trauma, including debridement).

Biologic wound therapy in PG is an area of evolving and very limited evidence, but the immunomodulatory mechanism of amniotic membrane (IL-1Ra blocking the IL-1β-driven neutrophil activation cascade central to PG pathogenesis) provides a mechanistic rationale. Case reports of amniotic membrane and MSC-conditioned medium application in PG have described favorable wound responses when systemic disease control was established concurrently. Practitioners should approach PG wound management with caution, avoiding aggressive debridement, and coordinating biologic wound care with the managing rheumatologist or dermatologist.

Ref: Binus AM, et al. Br J Dermatol. 2011;165(6):1264–1269 | Langan SM, et al. Br J Dermatol. 2018;179(6):1259–1263.
Clinical Decision Framework

Patient & Wound Selection for Biologic Therapy

Wound healing biologics produce their best results in wounds where the biologic’s mechanism directly addresses the primary failure mode — and fail when applied to wounds with unaddressed macrovascular disease, uncontrolled infection, or inadequate wound bed preparation.

Favorable Candidate Profile

  • Wound failing to achieve ≥30–50% area reduction after 4 weeks of optimized standard care — the published clinical trigger for advanced therapy escalation
  • Clean, granulating wound bed after adequate debridement — biologic products cannot penetrate devitalized tissue or biofilm
  • Adequate vascular supply confirmed — ABI ≥0.6 for lower extremity wounds; TcPO2 ≥30 mmHg at wound margin
  • Absence of active deep tissue infection — cellulitis or osteomyelitis requires antibiotic management before biologic application
  • Patient compliance with offloading (DFU), compression (VLU), or repositioning (pressure injury) protocols — biologics cannot overcome continued mechanical insult
  • Wound etiology identified and modifiable systemic factors addressed — glycemic control (HbA1c <9%), nutritional status (albumin >3 g/dL), medication review

Caution / Prerequisite Action Required

  • Active wound infection (cellulitis, osteomyelitis, purulent exudate) — treat infection first; biologics are not antimicrobials
  • Significant arterial insufficiency (ABI <0.5) — revascularization workup and intervention precede biologic eligibility assessment
  • Inadequate wound bed preparation — non-viable tissue, slough, and established biofilm must be debrided before biologic application
  • Uncontrolled systemic disease — HbA1c >11%, severe malnutrition (albumin <2 g/dL), or active autoimmune flare may substantially reduce biologic response
  • Tunneling or undermining exceeding 50% of wound circumference — surface biologic dressings cannot reach the wound base; packing and structural approaches required
  • Pyoderma gangrenosum — avoid debridement; coordinate systemic immunosuppression before any wound manipulation
Modality Comparison

Wound Healing Biologics at a Glance

Selecting the right biologic for the right wound requires understanding how each modality’s primary mechanism maps to the wound’s dominant failure mode.

Modality Primary Mechanism in Wounds Best Wound Type Format Evidence Level Storage
Lyo Amniotic Membrane TIMP-mediated MMP suppression; EGF/KGF keratinocyte stimulation; IL-1Ra anti-inflammatory DFU (strongest) · VLU · Burns Topical dressing / mask Level I (multiple RCTs) Ambient (15–25°C)
PRP Gel PDGF/TGF-β1 fibroblast stimulation; VEGF angiogenesis; autologous GF delivery DFU · Pressure injuries · Surgical dehiscence Gel (activated) / perilesional injection Level I (meta-analysis) Same-day preparation
Lyo ADM (Dermal Matrix) ECM scaffold for fibroblast ingrowth; collagen architecture template Full-thickness wounds with exposed structures Structural coverage / surgical Level II (prospective cohort) Ambient (15–25°C)
WJ-MSC / Conditioned Medium M1→M2 macrophage polarization; SASP suppression; anti-fibrotic HGF/TSG-6 Refractory chronic wounds; high-MMP environments Topical / wound irrigation Level III (prospective series) Specialized (per manufacturer)
MSC-Derived Exosomes miRNA-mediated macrophage reprogramming; M2 polarization; anti-fibrotic Diabetic wounds (investigational) Topical / wound irrigation Preclinical + Phase I Specialized
Cord Blood-Derived GFs Supraphysiologic neonatal GF density; VEGF/EGF/HGF angiogenesis + epithelialization Early clinical series (various wound types) Topical / wound coverage Level III–IV (early series) Per product
Safety Profile & Regulatory Context

Safety & Regulatory Considerations in Wound Healing Practice

Wound healing biologics carry an excellent overall safety profile — the external wound application format eliminates many procedural risks present in injectable biologic use. Key considerations center on product quality, wound bed preparation prerequisites, and the regulatory classification of specific products.

Procedural Safety

Topical application of lyophilized amniotic membrane, ADM, and PRP gel to wound beds carries minimal procedural risk when applied to appropriately prepared wound beds. The primary safety considerations are product-related (sterility, manufacturing quality) rather than technique-related — in stark contrast to injectable spine or joint biologics.

  • No reports of immune rejection from allogeneic amniotic membrane or ADM application in the published wound care literature — acellular products lack antigen-presenting cells
  • Autologous PRP applied to wound beds: infection risk <0.1% with sterile preparation; verify absence of bacteremia before PRP application to open wounds in immunocompromised patients
  • Product storage integrity: lyophilized products are robust to ambient temperature variation within their labeled range; inspect foil packaging integrity before use; do not use products with compromised packaging
  • Wound bed preparation is the primary procedural safety requirement — applying biologic coverage to infected or necrotic wound beds risks trapping pathogens under the product
  • Biological response monitoring: assess wound at each dressing change (typically weekly) for signs of excessive exudate, erythema, or wound bed deterioration indicating product failure or underlying infection

Regulatory Framework

Wound healing biologics represent the most mature and clearly delineated regulatory category in the HCT/P space, with several products cleared through established FDA pathways and Medicare/Medicaid coverage in the most common wound indications.

  • Lyophilized amniotic membrane wound products: regulated as HCT/Ps under 21 CFR Part 1271; multiple products carry AATB accreditation; several have CMS coverage for DFU and VLU indications (Q-code billing)
  • PRP for wound care: autologous, minimally manipulated, same-day use; Medicare National Coverage Determination (NCD 270.3) provides limited coverage for chronic non-healing wounds in select clinical contexts
  • Lyophilized ADM products: established HCT/P regulatory pathway; CMS coverage for specific wound indications under Q-codes
  • MSC-derived and exosome products: full CGTP compliance required; regulatory classification varies; verify current FDA status before procurement and clinical use
  • Documentation requirements: wound photography, wound measurements (length, width, depth), wound bed description, and prior treatment failure documentation are standard requirements for biologic wound product coverage authorization
Powered by Platinum Biologics

Access Wound Healing Biologics for Your Practice

OurBiologics partners with Platinum Biologics to provide AATB-accredited, FDA-registered biologics for wound management — including lyophilized amniotic membrane, acellular dermal matrix, and growth factor platform products for DFU, VLU, pressure injury, and surgical wound applications.

Request Product Information Explore All Modalities

The content on this page is intended for educational and informational purposes only and is directed at licensed healthcare professionals. It does not constitute medical advice, a wound care protocol, or a recommendation for any specific biologic product. Wound healing biologic applications should be implemented within a comprehensive wound care plan including wound bed preparation, infection control, offloading or compression as appropriate, and management of systemic comorbidities. Biologic products do not replace revascularization in ischemic wounds or surgical debridement in infected wounds. Clinical outcomes described in cited research are presented in their published context and may not be representative of results in routine clinical practice. Coverage and reimbursement for wound healing biologic products varies by payer, wound type, and documentation — practitioners are responsible for verifying coverage eligibility prior to treatment. Platinum Biologics and OurBiologics make no claims of efficacy for any specific wound indication.